Cue Biopharma, Inc.(CUE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CUE Cue Biopharma, Inc.

Trading 02-13 13:41:04 EST

0.3041

+0.0041

+1.37%

High0.3192	Low0.2950	Vol181.61K
Open0.3001	D1 Closing0.3000	Amplitude8.07%
Mkt Cap27.75M	Tradable Cap27.66M	Total Shares91.24M
T/O55.13K	T/O Rate0.20%	Tradable Shares90.97M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CUE","market":"US","secType":"STK","nameCN":"Cue Biopharma, Inc.","latestPrice":0.3041,"timestamp":1771008064639,"preClose":0.3,"halted":0,"volume":181607,"delay":0,"changeRate":0.013666666666666643,"floatShares":90972099,"shares":91237736,"eps":-0.43659,"marketStatus":"Trading","change":0.0041,"latestTime":"02-13 13:41:04 EST","open":0.3001,"high":0.3192,"low":0.295,"amount":55130.46967926,"amplitude":0.080667,"askPrice":0.307,"askSize":800,"bidPrice":0.304,"bidSize":61113,"shortable":3,"etf":0,"ttmEps":-0.43659,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1771016400000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1514869200000,"exchange":"NASDAQ","adjPreClose":0.3,"preHourTrading":{"tag":"盘前","latestPrice":0.3001,"preClose":0.3,"latestTime":"08:03 EST","volume":659,"amount":198.25549746000002,"timestamp":1770987800876,"change":0.0001,"changeRate":0.000333,"amplitude":0.136},"postHourTrading":{"tag":"盘后","latestPrice":0.32,"preClose":0.3,"latestTime":"19:46 EST","volume":6021,"amount":1855.9796,"timestamp":1770943585917,"change":0.02,"changeRate":0.066667,"amplitude":0.066667},"volumeRatio":0.635553,"impliedVol":0.7367,"impliedVolPercentile":0.6972},"requestUrl":"/m/hq/s/CUE","defaultTab":"news","newsList":[{"id":"2610692954","title":"Press Release: Cue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Financial and Business Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2610692954","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610692954?lang=en_us&edition=fundamental","pubTime":"2026-02-12 21:00","pubTimestamp":1770901200,"startTime":"0","endTime":"0","summary":"BOSTON, Feb. 12, 2026  -- Cue Biopharma, Inc. , a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune and inflammatory diseases, today announced that Lucinda Warren, who has served as Cue Biopharma's chief business officer  since September 2024, has been appointed chief financial and business officer  effective February 9, 2026.Ms. Warren added, \"I am honored to serve Cue Biopharma in this capacity, and I look forward to continuing to support the Company's corporate priorities and to be a part of this dedicated team.\"","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03160","BK4585","BK4604","R","BK4555","CUE","BK4022","TM","BK4588","BK4232","BK4139","BK4099"],"gpt_icon":0},{"id":"2605415865","title":"Cue Biopharma’s CUE-101 Trial Hits Completion: What It Means for Cancer Investors","url":"https://stock-news.laohu8.com/highlight/detail?id=2605415865","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605415865?lang=en_us&edition=fundamental","pubTime":"2026-01-23 00:30","pubTimestamp":1769099414,"startTime":"0","endTime":"0","summary":"Cue Biopharma ($CUE) announced an update on their ongoing clinical study. Cue Biopharma’s HPV-Linked Head and Neck Cancer Study Reaches Key Milesto...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cue-biopharmas-cue-101-trial-hits-completion-what-it-means-for-cancer-investors?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cue-biopharmas-cue-101-trial-hits-completion-what-it-means-for-cancer-investors?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4211","BK4139","ISBC","CUE"],"gpt_icon":0},{"id":"2600098472","title":"Director Pasha Sarraf Reports Acquisition of Cue Biopharma Inc. Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2600098472","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600098472?lang=en_us&edition=fundamental","pubTime":"2026-01-03 05:00","pubTimestamp":1767387642,"startTime":"0","endTime":"0","summary":"Pasha Sarraf, Director of Cue Biopharma Inc., has reported the acquisition of common shares of Cue Biopharma Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cue Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 02, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260102:nNDL2ZMFXk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Director Pasha Sarraf Reports Acquisition of Cue Biopharma Inc. Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CUE","BK4139"],"gpt_icon":0},{"id":"2592167800","title":"BRIEF-Cue Biopharma Announces Pricing Of $10 Million Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2592167800","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592167800?lang=en_us&edition=fundamental","pubTime":"2025-12-19 21:31","pubTimestamp":1766151069,"startTime":"0","endTime":"0","summary":"BRIEF-Cue Biopharma Announces Pricing Of $10 Million Public OfferingDec 19 (Reuters) - Cue Biopharma Inc CUE.O:CUE BIOPHARMA ANNOUNCES PRICING OF $10 MILLION PUBLIC OFFERINGCUE BIOPHARMA INC - SHARES ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251219:nTUA8G0D6B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CUE","BK4139"],"gpt_icon":0},{"id":"2592162804","title":"Cue Biopharma Inc - Shares and Warrants Sold at Combined Price of $0.28","url":"https://stock-news.laohu8.com/highlight/detail?id=2592162804","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592162804?lang=en_us&edition=fundamental","pubTime":"2025-12-19 21:00","pubTimestamp":1766149200,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251219:nTUA8G0D6B:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CUE","BK4139"],"gpt_icon":0},{"id":"2592818162","title":"Press Release: Cue Biopharma Announces Proposed Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2592818162","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592818162?lang=en_us&edition=fundamental","pubTime":"2025-12-19 05:02","pubTimestamp":1766091720,"startTime":"0","endTime":"0","summary":"BOSTON, Dec. 18, 2025  -- Cue Biopharma, Inc. , a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune disease, today announced that it is commencing an underwritten public offering of shares of its common stock  and accompanying warrants to purchase shares of common stock. In addition, Cue Biopharma intends to grant the underwriters an option for a period of 30 days to purchase up to an additional 15% of the shares of its common stock and/or warrants to purchase shares of common stock offered in the public offering. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering. All of the securities are being offered by Cue Biopharma.H.C. Wainwright & Co. is acting as sole book-running manager for the proposed offering. Newb","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4022","CUE","BK4232","R","BK4139"],"gpt_icon":0},{"id":"2585574321","title":"Cue Biopharma Chief Medical Officer Matteo Levisetti to Depart","url":"https://stock-news.laohu8.com/highlight/detail?id=2585574321","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585574321?lang=en_us&edition=fundamental","pubTime":"2025-11-21 05:00","pubTimestamp":1763672453,"startTime":"0","endTime":"0","summary":"Cue Biopharma Inc. announced that Chief Medical Officer Matteo Levisetti will depart from the company effective November 28, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cue Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 20, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251120:nNDL9PwZ8P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CUE","BK4139"],"gpt_icon":0},{"id":"2584792677","title":"Cue Biopharma and ImmunoScape Announce Strategic Collaboration to Develop Breakthrough Cell Therapy Approach for Solid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2584792677","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584792677?lang=en_us&edition=fundamental","pubTime":"2025-11-20 00:55","pubTimestamp":1763571340,"startTime":"0","endTime":"0","summary":"Nov 6 (Reuters) - Cue Biopharma Inc ::*CUE BIOPHARMA AND IMMUNOSCAPE ANNOUNCE STRATEGIC COLLABORATION TO DEVELOP BREAKTHROUGH CELL THERAPY APPROACH FOR SOLID TUMORS  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 06-NOV-202513:00:04.11 GMT","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nRSD91jp3Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CUE"],"gpt_icon":0},{"id":"2583465513","title":"BRIEF-Immunoscape Signs Deal With Cue Biopharma To Develop Solid Tumor Cancer Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2583465513","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583465513?lang=en_us&edition=fundamental","pubTime":"2025-11-14 02:37","pubTimestamp":1763059078,"startTime":"0","endTime":"0","summary":"BRIEF-Immunoscape Signs Deal With Cue Biopharma To Develop Solid Tumor Cancer TreatmentNov 13 (Reuters) - ImmunoScape:IMMUNOSCAPE: ENTERED IN-LICENSING DEAL WITH CUE BIOPHARMA FOR DEVELOPMENT OF NEW C","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nFWN3WP1WJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1023059063.AUD","BK4585","IE00BFTCPJ56.SGD","LU2112291526.USD","LU0109394709.USD","LU1983299246.USD","LU2242646821.SGD","LU1061106388.HKD","BK4581","LU0889565916.HKD","CUE","LU0868494617.USD","LU0289739699.SGD","LU2089984988.USD","LU0320765992.SGD","LU2242652126.USD","BK4599","AMGN","LU0058720904.USD","LU1057294990.SGD","SG9999001440.SGD","IE00B4R5TH58.HKD","BK4566","BK4534","IE0002141913.USD","IE00B2B36J28.USD","BK4533","LU0122379950.USD","BK4588","BK4139","LU1571399168.USD","IE0009355771.USD","LU2468319806.SGD","IE00BJJMRZ35.SGD","IE00BJT1NW94.SGD"],"gpt_icon":0},{"id":"2583851384","title":"Immunoscape: Entered in-Licensing Deal With Cue Biopharma for Development of New Class of Therapies to Attack Solid Tumor Cancers","url":"https://stock-news.laohu8.com/highlight/detail?id=2583851384","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583851384?lang=en_us&edition=fundamental","pubTime":"2025-11-14 02:15","pubTimestamp":1763057723,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nFWN3WP1WJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1061106388.HKD","LU0889565916.HKD","LU2089984988.USD","LU2242652126.USD","IE00B4R5TH58.HKD","LU1983299246.USD","LU0289739699.SGD","BK4139","LU2242646821.SGD","LU0122379950.USD","LU1057294990.SGD","CUE","LU1023059063.AUD","LU1571399168.USD","SG9999001440.SGD","BK4533","BK4599","BK4585","LU2112291526.USD","IE00BJJMRZ35.SGD","LU0109394709.USD","BK4534","BK4581","IE0002141913.USD","AMGN","IE00B2B36J28.USD","BK4566","LU2468319806.SGD","LU0320765992.SGD","IE0009355771.USD","LU0868494617.USD","BK4588","IE00BFTCPJ56.SGD","LU0058720904.USD","IE00BJT1NW94.SGD"],"gpt_icon":0},{"id":"2583138535","title":"Cue Biopharma Licenses Immuno-STAT® Oncology Technology to ImmunoScape","url":"https://stock-news.laohu8.com/highlight/detail?id=2583138535","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583138535?lang=en_us&edition=fundamental","pubTime":"2025-11-14 02:11","pubTimestamp":1763057486,"startTime":"0","endTime":"0","summary":"Cue Biopharma Inc. has announced an exclusive in-licensing agreement with Singapore-based ImmunoScape Pte. Ltd. Under the terms of the deal, ImmunoScape will gain exclusive access to Cue Biopharma's clinical-stage Immuno-STAT molecules for development in oncology. The collaboration aims to advance next-generation TCR-based cancer immunotherapies, particularly for solid tumor cancers.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cue Biopharma Inc. published the original content used to generate this news brief via Business Wire  on November 13, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nNDLSMryR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CUE"],"gpt_icon":0},{"id":"2583853975","title":"Cue Biopharma Q3 collaboration revenue falls","url":"https://stock-news.laohu8.com/highlight/detail?id=2583853975","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583853975?lang=en_us&edition=fundamental","pubTime":"2025-11-13 05:35","pubTimestamp":1762983324,"startTime":"0","endTime":"0","summary":"Cue Biopharma Q3 collaborationrevenue fallsOverviewCue Biopharma Q3 collaboration revenue declinesCompany announces $15 mln collaboration with ImmunoScape for cell therapy developmentOperating expense","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nL1N3WO14I:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CUE"],"gpt_icon":0},{"id":"2583090583","title":"Cue Biopharma Q3 EPS $(0.07) Beats $(0.09) Estimate, Sales $2.149M Miss $2.290M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2583090583","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583090583?lang=en_us&edition=fundamental","pubTime":"2025-11-13 05:32","pubTimestamp":1762983163,"startTime":"0","endTime":"0","summary":"Cue Biopharma Q3 EPS $(0.07) Beats $(0.09) Estimate, Sales $2.149M Miss $2.290M Estimate","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48820087/cue-biopharma-q3-eps-0-07-beats-0-09-estimate-sales-2-149m-miss-2-290m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Cue Biopharma Q3 EPS $(0.07) Beats $(0.09) Estimate, Sales $2.149M Miss $2.290M Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CUE"],"gpt_icon":0},{"id":"2583622588","title":"Cue Biopharma Names Usman Azam President and CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2583622588","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583622588?lang=en_us&edition=fundamental","pubTime":"2025-11-13 05:07","pubTimestamp":1762981629,"startTime":"0","endTime":"0","summary":"Cue Biopharma Inc. has announced a strategic transition in leadership, appointing Usman Azam, M.D., as President and Chief Executive Officer, effective September 29. This change is intended to support the company's next stage of growth, particularly in advancing its lead autoimmune asset, CUE-401.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cue Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire  on November 12, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nNDL14gz1t:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","IE00B3QW5Z07.USD","LU2210149790.SGD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","CUE","LU0314104364.USD","BK4588","NDAQ","LU2095319765.USD","IE00BKPKM429.USD","BK4585","BK4139","LU2210150020.SGD"],"gpt_icon":0},{"id":"2583158883","title":"Cue Biopharma Reports Third Quarter 2025 Financial Results and Recent Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2583158883","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583158883?lang=en_us&edition=fundamental","pubTime":"2025-11-13 05:05","pubTimestamp":1762981505,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nTUA58CG36:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CUE","BK4139"],"gpt_icon":0},{"id":"2581099851","title":"BRIEF-Cue Biopharma and ImmunoScape Announce Strategic Collaboration to Develop Breakthrough Cell Therapy Approach for Solid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2581099851","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581099851?lang=en_us&edition=fundamental","pubTime":"2025-11-06 21:51","pubTimestamp":1762437090,"startTime":"0","endTime":"0","summary":"BRIEF-Cue Biopharmaand ImmunoScape Announce Strategic Collaboration to Develop Breakthrough Cell Therapy Approach for Solid TumorsNov 6 (Reuters) - Cue Biopharma Inc CUE.O:CUE BIOPHARMA AND IMMUNOSCAP","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nTUA7H0SQP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CUE","BK4139"],"gpt_icon":0},{"id":"2572524260","title":"Cue Biopharma Inc. Files Initial Statement of Beneficial Ownership for CEO and Director Usman Azam","url":"https://stock-news.laohu8.com/highlight/detail?id=2572524260","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572524260?lang=en_us&edition=fundamental","pubTime":"2025-10-03 08:13","pubTimestamp":1759450439,"startTime":"0","endTime":"0","summary":"Cue Biopharma Inc. has filed an initial statement of beneficial ownership with the U.S. Securities and Exchange Commission. The filing names Usman Azam as the beneficial owner, who currently serves as Chief Executive Officer and Director of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cue Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 02, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251003:nNDL1MYJqY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CUE"],"gpt_icon":0},{"id":"2571576339","title":"BRIEF-Cue Biopharma Appoints New CEO, Shifts Focus to Autoimmune Therapies","url":"https://stock-news.laohu8.com/highlight/detail?id=2571576339","media":"Reuters","labels":["executive","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571576339?lang=en_us&edition=fundamental","pubTime":"2025-09-29 21:13","pubTimestamp":1759151616,"startTime":"0","endTime":"0","summary":"BRIEF-Cue Biopharma Appoints New CEO, Shifts Focus to Autoimmune Therapies Sept 29 (Reuters) - Cue Biopharma Inc CUE.O:CUE BIOPHARMA ANNOUNCES STRATEGIC TRANSITION IN LEADERSHIP TO FURTHER ENABLE NEXT","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250929:nTUA674NDP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CUE","BK4139"],"gpt_icon":0},{"id":"2571336230","title":"Cue Biopharma Appoints Usman Azam as CEO, Shifts Focus to Autoimmune Therapies as Daniel Passeri Becomes Strategic Advisor","url":"https://stock-news.laohu8.com/highlight/detail?id=2571336230","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571336230?lang=en_us&edition=fundamental","pubTime":"2025-09-29 21:00","pubTimestamp":1759150853,"startTime":"0","endTime":"0","summary":"Cue Biopharma Inc. has announced that Usman Azam, M.D., will become President and Chief Executive Officer effective September 29, 2025. Current CEO Daniel Passeri will transition to the role of Strategic Advisor. The company is prioritizing the development of its autoimmune disease programs, with a particular focus on advancing its CUE-401 therapeutic candidate into clinical trials.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cue Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire  on September 29, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250929:nNDL6BjqcV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","LU0314104364.USD","IE00BKPKM429.USD","BK4588","LU2210149790.SGD","LU2095319765.USD","NDAQ","BK4139","CUE","IE00B64PRP62.GBP","BK4112","BK4585","IE00BGHQF748.EUR","IE00B3QW5Z07.USD"],"gpt_icon":0},{"id":"2571733617","title":"Cue Biopharma Announces Strategic Transition in Leadership to Further Enable Next Stage of Growth With Disruptive Autoimmune Therapeutic Candidates","url":"https://stock-news.laohu8.com/highlight/detail?id=2571733617","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571733617?lang=en_us&edition=fundamental","pubTime":"2025-09-29 21:00","pubTimestamp":1759150800,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250929:nTUA674NDP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CUE"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cuebiopharma.com","stockEarnings":[{"period":"1week","weight":-0.0509},{"period":"1month","weight":-0.1443},{"period":"3month","weight":-0.5238},{"period":"6month","weight":-0.6368},{"period":"1year","weight":-0.7744},{"period":"ytd","weight":-0.0177}],"compareEarnings":[{"period":"1week","weight":0.0054},{"period":"1month","weight":-0.018},{"period":"3month","weight":0.0139},{"period":"6month","weight":0.0588},{"period":"1year","weight":0.1291},{"period":"ytd","weight":-0.001}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology; strategic collaboration and option agreement with Ono Pharmaceutical Co., Ltd. to advance CUE-401 for the treatment of autoimmune and inflammatory diseases; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.625,"avgChangeRate":0.050638},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.05062},{"month":3,"riseRate":0.25,"avgChangeRate":-0.04865},{"month":4,"riseRate":0.5,"avgChangeRate":0.067443},{"month":5,"riseRate":0.375,"avgChangeRate":0.000175},{"month":6,"riseRate":0.25,"avgChangeRate":-0.112726},{"month":7,"riseRate":0.375,"avgChangeRate":-0.091669},{"month":8,"riseRate":0.5,"avgChangeRate":-0.020243},{"month":9,"riseRate":0.375,"avgChangeRate":-0.04952},{"month":10,"riseRate":0.5,"avgChangeRate":0.074591},{"month":11,"riseRate":0.625,"avgChangeRate":0.074714},{"month":12,"riseRate":0.375,"avgChangeRate":-0.083168}],"exchange":"NASDAQ","name":"Cue Biopharma, Inc.","nameEN":"Cue Biopharma, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Cue Biopharma, Inc.(CUE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Cue Biopharma, Inc.(CUE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Cue Biopharma, Inc.,CUE,Cue Biopharma, Inc.股票,Cue Biopharma, Inc.股票老虎,Cue Biopharma, Inc.股票老虎国际,Cue Biopharma, Inc.行情,Cue Biopharma, Inc.股票行情,Cue Biopharma, Inc.股价,Cue Biopharma, Inc.股市,Cue Biopharma, Inc.股票价格,Cue Biopharma, Inc.股票交易,Cue Biopharma, Inc.股票购买,Cue Biopharma, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Cue Biopharma, Inc.(CUE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Cue Biopharma, Inc.(CUE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction